Glax­o­SmithK­line re­thinks strat­e­gy for Covid-19 an­ti­body — not the Vir ones — af­ter tri­al flop. Is there hope in high-risk pa­tients?

In the search for a bet­ter Covid-19 ther­a­peu­tic, Glax­o­SmithK­line and Vir have part­nered up on two an­ti­bod­ies they hope have a chance. GSK is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.